BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 23591714)

  • 21. Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.
    Dosani T; Covut F; Pinto R; Kim BG; Ali N; Beck R; Maitta R; Downes K; Fox R; Reese J; de Lima M; Malek E
    Leuk Lymphoma; 2019 Sep; 60(9):2199-2206. PubMed ID: 30845862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
    Elayan MM; Horowitz JG; Magraner JM; Shaughnessy PJ; Bachier C
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
    Skopec B; Skerget M; Zontar D; Zadnik V; Zver S
    Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
    Micallef IN; Ho AD; Klein LM; Marulkar S; Gandhi PJ; Calandra G; McSweeney PA
    Bone Marrow Transplant; 2011 Mar; 46(3):350-5. PubMed ID: 20479709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
    Baertsch MA; Mai EK; Hielscher T; Bertsch U; Salwender HJ; Munder M; Fuhrmann S; Dührsen U; Brossart P; Neben K; Schlenzka J; Kunz C; Raab MS; Hillengaß J; Jauch A; Seckinger A; Hose D; Luntz S; Sonneveld P; Lokhorst H; Martin H; Goerner M; Hoffmann M; Lindemann HW; Bernhard H; Blau IW; Scheid C; Besemer B; Weisel KC; Hänel M; Dürig J; Goldschmidt H;
    Blood Cancer J; 2021 Jan; 11(1):1. PubMed ID: 33414374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis.
    Cowan AJ; Stevenson PA; Green DJ; Tuazon S; Libby EN; Kwok M; Lee S; Coffey DG; Gopal AK; Holmberg LA
    Transplant Cell Ther; 2021 Aug; 27(8):661.e1-661.e6. PubMed ID: 33895403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.
    Abid MB; De Mel S; Abid MA; Yap ES; Gopalakrishnan SK; Chen Y; Yuen YC; Wong HC; Lin A; Poon LM; Koh LP; Chng WJ; Tan LK
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):174-179. PubMed ID: 29398647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.
    Damron EP; Qazilbash MH; Fang PQ; Wu SY; Dabaja BS; Rondon G; Hosing C; Champlin RE; Bashir Q; Shpall EJ; Knafl MK; Lee HC; Manasanch EE; Patel K; Thomas SK; Orlowski RZ; Weber DM; Pinnix CC; Gunther JR
    Transplant Cell Ther; 2023 Jan; 29(1):37.e1-37.e7. PubMed ID: 37753818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
    Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
    Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
    Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
    D'Addio A; Curti A; Worel N; Douglas K; Motta MR; Rizzi S; Dan E; Taioli S; Giudice V; Agis H; Kopetzky G; Soutar R; Casadei B; Baccarani M; Lemoli RM
    Bone Marrow Transplant; 2011 Mar; 46(3):356-63. PubMed ID: 20577218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
    Mark T; Stern J; Furst JR; Jayabalan D; Zafar F; LaRow A; Pearse RN; Harpel J; Shore T; Schuster MW; Leonard JP; Christos PJ; Coleman M; Niesvizky R
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):795-8. PubMed ID: 18541199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Tuchman SA; Bacon WA; Huang LW; Long G; Rizzieri D; Horwitz M; Chute JP; Sullivan K; Morris Engemann A; Yopp A; Li Z; Corbet K; Chao N; Gasparetto C
    J Clin Apher; 2015 Jun; 30(3):176-82. PubMed ID: 25293363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
    Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
    Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.
    Musto P; Simeon V; Grossi A; Gay F; Bringhen S; Larocca A; Guariglia R; Pietrantuono G; Villani O; D'Arena G; Cuomo C; Musto C; Morabito F; Petrucci MT; Offidani M; Zamagni E; Tacchetti P; Conticello C; Milone G; Palumbo A; Cavo M; Boccadoro M
    Stem Cell Res Ther; 2015 Apr; 6(1):64. PubMed ID: 25889496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
    Rybinski B; Rapoport AP; Badros AZ; Hardy N; Kocoglu M
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e716-e729. PubMed ID: 35504807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: A single-center retrospective analysis.
    Dill V; Blüm P; Lindemann A; Biederstädt A; Högner M; Götze KS; Bassermann F; Hildebrandt M
    Transfusion; 2024 May; 64(5):871-880. PubMed ID: 38600674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
    Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
    J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of lenalidomide-based induction therapy on the mobilization of CD34
    Partanen A; Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Putkonen M; Sankelo M; Pelkonen J; Mäntymaa P; Varmavuo V; Jantunen E
    Transfusion; 2017 Oct; 57(10):2366-2372. PubMed ID: 28681435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.